Morphogenesis’ development resources are focused on conducting clinical trials required by regulatory authorities to fully answer important scientific questions about the potential risks and benefits of our investigational products (also called new medicines), and to obtain regulatory approval.
Morphogenesis is committed to making investigational products available to seriously ill patients who have exhausted other treatment options. A treating physician, who is able to comply with the requirements of our policy, may request information about how to apply for expanded access to Morphogenesis’ investigational products.
Any use of a Morphogenesis investigational product outside a clinical trial in any country, must be in accordance with local laws and regulations governing such programs, including Morphogenesis’ own policies and procedures.
Request forms must be submitted by a healthcare professional. Patient eligibility will be determined by Morphogenesis in accordance with established policies and procedures. Morphogenesis' acknowledgement of receipt and processing of a request does not guarantee that access to the investigational product will be provided.
Morphogenesis will typically acknowledge receipt of a request for expanded access within three business days.